Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01189 (
beta-endorphin
)
21,003
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The Agouti Related Protein (AGRP) is an endogenous antagonist of melanocortin-3 and -4 receptors, each of which plays a key role in body weight homeostasis. We designed a peptoid trimer based on AGRP 111-113 in which a single chiral atom is used to partially restrain the backbone structure. Peptoid 5 displaced both radiolabeled Nle4-
alpha-MSH
(IC(50)=3.1 microM) and AGRP (86-132) (IC(50)=1.9 microM) from the human
melanocortin-4 receptor
and functioned as an antagonist of
alpha-MSH
stimulated cAMP generation, thus providing an important lead in the development of AGRP mimetics.
...
PMID:Peptoid mimics of agouti related protein. 1266 1
The
melanocortin-4 receptor
(
MC4R
) plays an important role in the regulation of body weight in rodents. Mutations in the coding region of the
MC4R
are found more frequently in obese individuals, supporting the hypothesis that also in humans deficient melanocortin signaling may lead to obesity. Family studies that were carried out to demonstrate the relevance of single mutations for obesity were mostly inconclusive, most likely due to small sample size and complexity of the trait. In addition, the existing pharmacological data of the mutant receptors are limited in that for most mutations the effect on receptor expression level and Agouti-related protein (AgRP) pharmacology have not been studied. The aim of the present study was to gain further insight into the impact of the
MC4R
mutations on receptor function. Eleven missense mutations were tested for cell surface expression, affinity for
alpha-melanocyte-stimulating hormone
(
alpha-MSH
) and AgRP-(83-132), and the biological response to
alpha-MSH
. All mutants were poorly expressed at the cell surface, as measured by 125I-[Nle4-D-Phe7]
alpha-MSH
binding, and only a few mutants showed altered pharmacology for
alpha-MSH
and AgRP. Hemagglutinin-tagged mutant receptors were retained in the intracellular environment. These pharmacological data provide a basis to estimate the quantitative effect of
MC4R
mutations for the development of obesity.
...
PMID:Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity. 1269 Jan 2
alpha-Melanocyte stimulating hormone (MSH) has generally been assumed to be the endogenous ligand acting at the
melanocortin-4 receptor
(
MC4-R
), activation of which in the hypothalamus leads to reduced feeding. However,
beta-MSH
is also capable of activating
MC4-R
and inhibiting feeding. Here, we investigated the possibility that
beta-MSH
acts as an endogenous
MC4-R
agonist and that this melanocortin peptide plays a role in the regulation of feeding and energy balance. We found that
beta-MSH
had significantly higher affinities than
alpha-MSH
at both human
MC4-R
transfected into CHO cells (K(i):
beta-MSH
, 11.4+/-0.4 nmol/l versus
alpha-MSH
, 324+/-16 nmol/l, P<0.001) and
MC4-R
in rat hypothalamic homogenates (K(i):
beta-MSH
, 5.0+/-0.4 nmol/l versus
alpha-MSH
, 22.5+/-2.3 nmol/l, P<0.001). Incubation of brain slices with 5 microM
beta-MSH
significantly increased [35S]GTPgammaS binding by 140-160% (P<0.001), indicating activation of G-protein-coupled receptors (GPCRs), in the hypothalamic ventromedial (VMH), dorsomedial (DMH), arcuate (ARC) and paraventricular (PVN) nuclei. These sites match the distribution of
beta-MSH
immunoreactive fibres and also the distribution of
MC4-R
binding sites which we and others previously reported. Food-restriction significantly increased
beta-MSH
levels in the VMH, DMH and ARC (all P<0.05) above freely-fed controls, whilst
alpha-MSH
concentrations were unchanged. We propose that increased
beta-MSH
concentrations reflect blockade of the peptide's release in these sites, consistent with the increased hunger and the known up-regulation of
MC4-R
in the same nuclei. Thus, we conclude that (1).
beta-MSH
has higher affinity at
MC4-R
than
alpha-MSH
; (2).
beta-MSH
activates GPCR in these sites, which are rich in
MC4-R
; and (3).
beta-MSH
is present in hypothalamic nuclei that regulate feeding and its concentrations alter with nutritional state. We suggest that
beta-MSH
rather than
alpha-MSH
is the key ligand at the
MC4-R
populations that regulate feeding, and that inhibition of tonic release of
beta-MSH
is one mechanism contributing to hunger in under-feeding.
...
PMID:beta-MSH: a functional ligand that regulated energy homeostasis via hypothalamic MC4-R? 1273 37
G-protein-coupled receptors (GPCRs) are the largest known family of cell surface receptors, and they control many important physiological events, including sensory perception, chemotaxis, neurotransmission, and energy homeostasis. However, GPCR signaling can be difficult to study in vivo because of the multitude of GPCRs, the lack of specific synthetic agonists, and the fact that some GPCRs activate multiple signaling pathways. One method to circumvent these problems is to develop an engineered receptor that is unresponsive to its endogenous agonist, yet can be fully activated by synthetic, small-molecule drugs. Such a receptor, called a receptor activated solely by a synthetic ligand (RASSL), can be rapidly and reversibly activated by a small-molecule drug and would be a powerful tool to control G-protein signaling in vivo. Here we present the development of a G(s)-coupled RASSL based on the
melanocortin-4 receptor
(
MC4R
).
MC4R
couples exclusively to G(s) at physiologically relevant concentrations of its endogenous ligand,
alpha-melanocyte-stimulating hormone
(
alpha-MSH
). Data from human patients and structure-activity studies have shown that several mutations in
MC4R
cause a decreased affinity for
alpha-MSH
and can be exploited for RASSL development. Synthetic, small-molecule agonists of
MC4R
are now available and can be used to activate mutated receptors in vivo. We are engineering a series of mutations in
MC4R
to remove the peptide-binding site while retaining small-molecule binding and activation. The
MC4R
G(s) RASSL could be used to control many physiological responses associated with G(s) signaling such as heart rate, energy homeostasis, and cell proliferation.
...
PMID:Engineering the melanocortin-4 receptor to control G(s) signaling in vivo. 1285 20
Both central
alpha-melanocyte-stimulating hormone
and
corticotropin
-releasing hormone (CRH) have been implicated in feeding and neuroendocrine mechanisms. The anatomical overlap and functional similarities between these two neurotransmitter systems led to the hypothesis that CRH might act as one of the mediators of the central actions of the melanocortin system. By double-labeling in situ hybridization, a subpopulation of CRH neurons in the paraventricular nucleus of the hypothalamus (PVN) were shown to contain the
melanocortin-4 receptor
(
MC4R
), concentrated in the ventromedial part of the parvicellular PVN (up to 33%). Intracerebroventricular injection of melanocortin agonist MTII to conscious and freely moving rats induced a rapid induction of CRH gene transcription in the PVN. This effect was accompanied by a rise in plasma corticosterone levels in a dose- and time-dependent manner, with the maximum response observed 30 min after MTII injection. MTII (0.5 nmol)-induced increase in plasma corticosterone was attenuated by the selective
MC4R
antagonist HS014 (0.25-1.0 nmol) and nonselective CRH receptor antagonist alpha-helical-CRH9-41 (0.125-0.5 nmol) in a dose-dependent manner. Moreover, the anorectic effect of MTII was evaluated at 1, 2, and 24 hr after intracerebroventricular injection. Approximately half of the inhibitory effect of MTII (0.5 nmol) on food intake was reversed by pretreatment with alpha-helical-CRH9-41 at 0.25 and 0.5 nmol doses. Collectively, these results provide evidence that CRH acts as a downstream mediator of melanocortin signaling and contributes to the mechanisms by which the central melanocortin system controls feeding and neuroendocrine responses.
...
PMID:Interaction between alpha-melanocyte-stimulating hormone and corticotropin-releasing hormone in the regulation of feeding and hypothalamo-pituitary-adrenal responses. 1294 16
The
melanocortin-4 receptor
(
MC4R
) is a member of the rhodopsin-like G protein-coupled receptor family. The binding of
alpha-MSH
to the
MC4R
leads to increased cAMP production. Recent pharmacological and genetic studies have provided compelling evidence that
MC4R
is an important regulator of food intake and energy homeostasis. Allelic variants of
MC4R
were reported in some children with early-onset severe obesity. However, few studies have been performed to confirm that these allelic variants result in an impairment of the receptor's function. In this study, we expressed wild-type and variant MC4Rs in HEK293 cells and systematically studied ligand binding, agonist-stimulated cAMP, and cell surface expression. Six of the 11 mutants examined had either decreased (S58C, N62S, Y157S, C271Y) or no (P78L, G98R) ligand binding, with proportional impairments in [Nle4, d-Phe7]-
alpha-MSH
-stimulated cAMP production. Confocal microscopy confirmed that the observed decreases in hormone binding by these mutants are associated with decreased cell surface expression due to intracellular retention of the mutants. The other five allelic variants (D37V, P48S, V50M, I170V, N274S) were found to be expressed at the cell surface and to bind agonist and respond with increased cAMP production normally. The data on these latter five variants raise the question as to whether they are indeed causative of the obesity or not and, if so, by what mechanism. Our data, therefore, stress the importance of characterizing the properties of
MC4R
variants associated with early-onset severe obesity. We further propose a classification scheme for mutant MC4Rs based upon their properties.
...
PMID:Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity. 1295 94
A chimeric protein comprised of
melanocortin-4 receptor
(
MC4R
) and the green fluorescent protein (GFP) was created for studying receptor/ligand localization and trafficking. The ligand binding affinities and second messenger stimulation induced by
MC4R
-GFP closely resembled those of the wild-type receptor, suggesting functional integrity of the chimeric protein. As observed with a confocal microscope, in human embryonic kidney (HEK)-293 cells
MC4R
/GFP was distributed evenly along the cell membrane. Addition of [Nle4-d-Phe7]-
alpha-melanocyte-stimulating hormone
(NDP-MSH), a peptide
MC4R
agonist, induced receptor translocation into intracellular compartments in a time- and concentration-dependent manner. [Ac-Nle-c[Asp-His-d-Nal(2')-Arg-Trp-Lys]-NH2] (SHU9119), a potent
MC4R
antagonist, completely inhibited NDP-MSH-mediated internalization.
MC4R
-GFP internalization was unaffected by a protein kinase A inhibitor N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89), but was impaired by pretreatment with inhibitors of endocytosis through clathrin-coated pits, hypertonic sucrose, or concanavalin A. Time-dependent colocalization of
MC4R
-GFP with rhodamine-transferrin, an early endosome marker, and with LysoTraker, a lysosome marker, was observed after short-term (45 min) and prolonged (20 h) agonist exposure, respectively. Rhodamine-[AcNle-c[Asp-His-d-Phe-Arg-Trp-Lys]-NH2] (MTII), a fluorescent derivative of an
MC4R
agonist, was found to cointernalize with
MC4R
-GFP into intracellular vesicles. No significant receptor recycling or segregation from the ligand was observed 60 min after removal of the agonist. In contrast, an antagonist rhodamine-Ac-Cys-Glu-His-(d-Nal)-Arg-Trp-Gly-Cys-Pro-Pro-Lys-Asp-NH2 (HS014) bound to and colocalized with
MC4R
-GFP on the cell surface and did not stimulate receptor internalization. In sum, these results suggest that
MC4R
is subject to agonist-dependent endocytosis via clathrin-coated pits. Prolonged agonist exposure directs
MC4R
into lysosomes, possibly for degradation. Receptor and ligand recycling is not efficient for
MC4R
in HEK-293 cells.
...
PMID:Agonist-dependent internalization of the human melanocortin-4 receptors in human embryonic kidney 293 cells. 1453 63
In young (35- to 56-day-old) and middle-aged (9-mo-old) wild-type (+/+) and
melanocortin-4 receptor
(
MC4R
)-deficient (+/-, -/-) mice, expressions of neuropeptide Y (NPY), agouti-related protein (AGRP),
pro-opiomelanocortin (POMC)
, and cocaine-and-amphetamine-regulated transcript (CART) were analyzed in the arcuate nucleus (ARC) and adjacent regions comprising the dorsomedial (DMN) and ventromedial (VMN) nucleus. In the ARC of young mice, NPY and AGRP expression increased and POMC and CART expression decreased with body fat content. Adjusting for the influence of body fat content by ANCOVA showed that the levels of NPY, POMC, and CART were highest and of AGRP lowest in young -/- mice. In the middle-aged mice, feedback from body fat content was weakened. For -/- mice ANCOVA revealed higher NPY and AGRP, lower POMC, and unchanged CART expression levels relative to young -/- mice. In the DMN and VMN, POMC and AGRP signals were absent at each age. CART was expressed in the DMN independent of age, fat content, and genotype. For NPY expression, an age-dependent induction was found in the DMN and VMN; it was absent in the young but present in the middle-aged mice, showing close positive correlations between body fat content and the numbers of NPY-labeled cells which were further enhanced in -/- mice. Thus
MC4R
deficiency augments age-induced NPY expression in the DMN and VMN with no feedback from body fat content. Negative feedback control by body fat content on ARC neuropeptide expression is present in young animals but vanishes with age and is modulated by
MC4R
deficiency.
...
PMID:Age-dependent hypothalamic expression of neuropeptides in wild-type and melanocortin-4 receptor-deficient mice. 1455 77
Anorexia is one of the common symptoms caused by various psychiatric disorders. Increasing evidence indicates that neuroleptics can induce weight gain, obesity, and diabetes mellitus. However, the mechanisms underlying these conditions have not been fully elucidated. In this review, we describe molecular neuroanatomic aspects of current biology of energy homeostasis that would help to address the psychiatric issues noted above, focusing on the central leptin/melanocortin system. An adipocyte-derived hormone, leptin acts on the arcuate hypothalamic nucleus (Arc) to inhibit feeding behavior and simultaneously to promote energy expenditure. Leptin activates Arc neurons producing
alpha-melanocyte-stimulating hormone
(
alpha-MSH
) and inhibits those producing agouti-related protein (AgRP).
alpha-MSH
is an endogenous agonist for the
melanocortin-4 receptor
(
MC4-R
) that is expressed exclusively in the central nervous system (CNS), whereas AgRP acts as a
MC4-R
antagonist. It is also established that
MC4-R
blockade produces an over-eating/obesity syndrome in rodents and humans. Thus,
MC4-R
-expressing neurons are downstream targets of leptin. Of interest,
MC4-R
-positive neurons densely populate in CNS sites critical for energy homeostasis and associated with psychiatric disorders, including the paraventricular hypothalamic nucleus and central amygdaloid nucleus. In addition, Arc
alpha-MSH
neurons receive serotonergic inputs from raphe neurons. Finally, an AgRP gene polymorphism has been associated with anorexia nervosa. These findings suggest that the central melanocortin system is a target for psychiatry.
...
PMID:[Psychiatric disorders and neural mechanisms underlying energy intake and expenditure: a review]. 1465 25
Genetic, biochemical and pharmacological studies in humans and rodents have established that signalling through the G-protein-coupled
melanocortin-4 receptor
(
MC4R
) by
pro-opiomelanocortin (POMC)
-derived ligands plays a critical role in the central suppression of appetite. As a consequence, malfunction of this signalling system leads to the development of obesity. It has been shown previously that melanocortin signalling can be modulated by the type 1 transmembrane protein attractin, apparently acting as a co-receptor for the inhibitory ligand agouti. Work reported in this issue of Biochemical Journal (Haqq et al.) demonstrates that the cytosolic tail of an attractin-like protein (ALP) binds directly and specifically to the C-terminal region of
MC4R
, raising the possibility that proteins of the attractin family influence melanocortin receptor function through multiple mechanisms.
...
PMID:Attractin' more attention - new pieces in the obesity puzzle? 1453 29
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>